Geron-logo-black-xsmall.png
Geron Corporation Reports Fourth Quarter and Full Year 2019 Financial Results and 2020 Milestones
March 12, 2020 16:05 ET | Geron Corporation
MENLO PARK, Calif., March 12, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat,...
Geron-logo-black-xsmall.png
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 21, 2019 08:00 ET | Geron Corporation
MENLO PARK, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 150,000 shares of...
Geron-logo-black-xsmall.png
Geron Corporation Reports Third Quarter 2019 Financial Results and Recent Events
November 06, 2019 16:10 ET | Geron Corporation
MENLO PARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the third quarter and year-to-date as of September 30, 2019 as well as...
Geron-logo-black-xsmall.png
Geron Announces Two Poster Presentations at Upcoming American Society of Hematology Annual Meeting
November 06, 2019 09:18 ET | Geron Corporation
MENLO PARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that two abstracts related to imetelstat, the Company’s first-in-class telomerase inhibitor,...
Geron-logo-black-xsmall.png
Geron to Announce Third Quarter Financial Results on November 6, 2019
October 31, 2019 08:00 ET | Geron Corporation
MENLO PARK, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it will release its third quarter 2019 financial results after the market closes on...
Geron-logo-black-xsmall.png
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 17, 2019 16:10 ET | Geron Corporation
MENLO PARK, Calif., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 200,000 shares of...
Geron-logo-black-xsmall.png
Geron Announces First Patient Dosed in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes
October 10, 2019 17:30 ET | Geron Corporation
MENLO PARK, Calif., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the first patient has been dosed in the IMerge Phase 3 clinical trial to evaluate...
Geron-logo-black-xsmall.png
Geron Announces Fast Track Designation Granted to Imetelstat for Relapsed/Refractory Myelofibrosis
September 30, 2019 16:19 ET | Geron Corporation
MENLO PARK, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation...
Geron-logo-black-xsmall.png
Geron to Present at 2019 Cantor Global Healthcare Conference
September 26, 2019 16:18 ET | Geron Corporation
MENLO PARK, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to present a...
Geron-logo-black-xsmall.png
Geron Starts Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes
August 08, 2019 08:08 ET | Geron Corporation
MENLO PARK, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the opening of patient screening and enrollment for the Phase 3 portion of IMerge to evaluate...